Real-world Study on Adjuvant Octreotide Therapy in pNETs

Summary

Adjuvant therapy in pancreatic neuroendocrine tumors (pNETs) after radical resection lacks evidence-based data and is controversial. Real-world data were clustered to validate whether the long-acting octreotide is a potential candidate for adjuvant therapy in high recurrence risk G2 pNET patients.

Timeline

Start

2008-03

Primary completion

2020-04

Completion

2020-04

Drugs

Indications